Testosterone Formulations Billing & Prior-Auth Playbook

What the Six Testosterone Formulation Classes Are and How They Differ

The FDA recognizes six major delivery classes for testosterone replacement: intramuscular/subcutaneous injectables, transdermal gels, transdermal patches, buccal systems, nasal gels, and long-acting injectable esters (undecanoate). Each class produces a different pharmacokinetic profile, which matters clinically and matters enormously for billing because payers encode step-therapy rules around these distinctions. FDA prescribing information for testosterone formulations is catalogued at the agency's drug database.

Injectables: Cypionate and Enanthate

Testosterone cypionate and testosterone enanthate are the workhorses of TRT. Both are esterified testosterone dissolved in oil, administered IM or subcutaneously. Cypionate has a half-life of roughly 8 days; enanthate sits at approximately 4.5 days. The Endocrine Society's 2018 clinical practice guideline recommends testosterone cypionate or enanthate 75 to 100 mg IM weekly, or 150 to 200 mg every 2 weeks, as first-line options. Generic availability keeps monthly costs at $15, $60 for the drug itself, making injectables the default preferred tier on virtually every commercial formulary.

Subcutaneous delivery at 50 to 100 mg weekly produces steadier serum levels than the traditional IM every-2-week schedule, with peak-to-trough ratios that approximate physiologic diurnal variation more closely. A 2017 pharmacokinetic study published in PubMed (PMID 28672319) confirmed subcutaneous testosterone cypionate achieved stable trough levels without the supraphysiologic peaks associated with high-dose biweekly IM dosing.

Transdermal Gels

AndroGel, Testim, Fortesta, and Vogelxo are the primary branded gels. Generic testosterone 1% and 1.62% gels exist but carry varying therapeutic equivalence ratings. Gels allow once-daily application and avoid injection-site discomfort, which improves adherence in certain patient populations. The transfer-risk concern (skin-to-skin contact transmitting testosterone to women or children) is real and FDA-labeled. The FDA issued a black-box warning in 2009 regarding secondary exposure to testosterone gel in children.

From a billing standpoint, gels almost always sit on a non-preferred or specialty tier. Expect a prior-auth requirement and, in most commercial plans, a mandatory step-through injectable failure before the gel is approved.

Patches, Nasal Gel, and Buccal Systems

Androderm (transdermal patch) delivers 2 or 4 mg/day. Natesto (nasal gel) doses at 11 mg (5.5 mg per nostril) three times daily and preserves hypothalamic-pituitary-gonadal axis function better than other formulations, making it relevant for men pursuing fertility. A 2015 study in the Journal of Sexual Medicine found Natesto produced mean trough testosterone of 305 ng/dL while maintaining sperm concentrations above 15 million/mL in most subjects. Striant (buccal system) is a 30 mg mucoadhesive tablet applied twice daily to the gum above the incisor.

These three classes are almost universally non-preferred and require prior authorization. Step-therapy requirements typically mandate documented failure or intolerance of both an injectable and a generic gel before approval.

Testosterone Undecanoate (Aveed and Jatenzo)

Aveed is a 750 mg/3 mL castor-oil IM injection dosed at 0, 4, and then every 10 weeks. It carries an FDA Risk Evaluation and Mitigation Strategy (REMS) due to serious pulmonary oil microembolism and anaphylaxis risk; it must be administered in a certified healthcare setting with a 30-minute observation period. The Aveed REMS program is maintained by the FDA at this address.

Jatenzo is the oral undecanoate formulation (237 mg twice daily, titrated). Its absorption depends on dietary fat, and it requires blood pressure monitoring given a mean 3 to 5 mmHg systolic increase in clinical trials. The FDA approval summary for Jatenzo notes the cardiovascular labeling requirement. Both undecanoate products occupy the highest cost and most restrictive prior-auth tier.

ICD-10 Coding: Getting the Diagnosis Right the First Time

Correct ICD-10 coding is the single fastest way to cut first-pass denial rates. Payers audit testosterone claims specifically because the drug class has been associated with off-label use for age-related decline, which most commercial plans exclude.

Primary vs. Secondary Hypogonadism

E29.1 (Testicular hypofunction / primary hypogonadism): Use when the testes are the source of dysfunction. Etiologies include Klinefelter syndrome (Q98.0), orchitis sequelae, cryptorchidism history, or chemotherapy-induced gonadal failure.

E23.0 (Hypopituitarism / secondary hypogonadism): Use when the deficit originates at the pituitary or hypothalamus. Low LH and FSH with low testosterone confirm secondary etiology. Many payers treat E23.0 with less skepticism because the organic cause is more demonstrable on lab panels.

Z79.890 (Long-term current use of hormonal contraceptives / androgenic hormones): Append this code on every refill claim. It signals the payer that this is maintenance therapy, not an acute initiation, reducing the frequency of step-therapy re-challenges.

Supporting Diagnosis Codes

Pair the primary hypogonadism code with relevant comorbidity codes to build a medically necessary narrative: E11.65 (type 2 diabetes with hyperglycemia), E78.5 (hyperlipidemia), or F32.A (depression, unspecified) are common comorbidities that correlate with testosterone deficiency and strengthen the clinical record. The Endocrine Society guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels."

Prior Authorization: Documentation That Actually Gets Approved

The Lab Package Payers Require

Most commercial payers and Medicare Advantage plans require all of the following before approving testosterone therapy:

• Two fasting morning total testosterone values <300 ng/dL (drawn between 07:00 to 10:00), collected on separate days at least one week apart
• LH and FSH to differentiate primary from secondary etiology
• Prolactin (to rule out prolactinoma in secondary cases)
• Hematocrit <54% at baseline
• PSA <4 ng/mL (or a documented discussion with urology if 2.5 to 4 ng/mL)

The American Urological Association guideline on testosterone deficiency syndrome specifies morning testosterone drawn on two separate occasions before initiating therapy.

Submitting all six data points with the initial PA request reduces back-and-forth by eliminating the most common additional-information requests. Missing even one lab is the leading reason for a peer-to-peer call requirement.

Documenting Symptoms Quantitatively

Payers increasingly reject PA requests that list symptoms as narrative text without a validated instrument. Use the Androgen Deficiency in Aging Males (ADAM) questionnaire or the International Index of Erectile Function (IIEF-5). A positive ADAM screen (positive responses to questions 1 or 7, or any three other questions) combined with two below-threshold testosterone values meets the clinical threshold in most guidelines. The original ADAM questionnaire validation was published in PMID 10872048.

Document the score numerically in the chart note and reference it explicitly in the PA clinical rationale field. "Patient scores 7/10 on ADAM with positive responses to questions 1, 5, and 7" carries more weight than "patient reports fatigue and low libido."

Step-Therapy Navigation

The table below maps the most common commercial payer step-therapy sequences and the documentation needed at each step. Prescribers who submit step-therapy exception requests without this documentation will almost always be denied at the plan level.

| Step | Formulation Class | Minimum Trial Duration | Exception Criterion | |------|------------------|----------------------|---------------------| | 1 | Generic injectable (cypionate or enanthate) | 90 days | Needle phobia (documented), coagulopathy, polycythemia on injectable | | 2 | Generic topical gel (1% or 1.62%) | 60 days | Transfer-risk to household members, skin condition precluding application | | 3 | Branded non-preferred (patch, nasal, buccal) | PA required | Failure/intolerance of steps 1 and 2 | | 4 | Undecanoate (Aveed or Jatenzo) | PA + REMS/BP monitoring | Failure of steps 1 to 3 or specific clinical indication |

For Medicare Part D, note that testosterone is classified as a "protected class" medication in some regional plans but not uniformly. CMS does not designate androgens as one of the six protected classes (antidepressants, antipsychotics, anticonvulsants, antiretrovirals, immunosuppressants, antineoplastics), so step-therapy and quantity limits apply broadly.

Writing the Peer-to-Peer Call Script

When a PA is denied and you request a peer-to-peer review, the reviewing clinician on the payer side is frequently a family medicine or internal medicine physician with limited endocrinology training. Lead with:

1. Diagnosis specificity: "This is E29.1 with confirmed primary hypogonadism, not age-related decline. FSH is 18 IU/L, LH is 16 IU/L, karyotype confirmed 46,XY."
2. Lab dates and values verbatim: "Total testosterone 187 ng/dL on 2025-01-03 at 08:15 and 214 ng/dL on 2025-01-10 at 08:45, both fasting."
3. Step-therapy exception reason precisely matched to plan criteria: "Patient is on warfarin with INR target 2.5 to 3.5, making IM injection a bleeding-risk contraindication per the plan's own exception criteria on page 14 of the formulary guide."

Peer-to-peer overturn rates improve substantially when the prescriber quotes the plan's own exception language back to the reviewing clinician.

Formulary Tier Management and Cost-Reduction Strategies

Generic Injectable as Anchor

Testosterone cypionate 200 mg/mL (10 mL multi-dose vial) consistently lands on Tier 1 or Tier 2 on commercial formularies. At a dose of 100 mg weekly, one 10 mL vial provides a 20-week supply, making the out-of-pocket cost under most plans roughly $5, $15/month after copay. This math matters when counseling patients who push for branded gels primarily due to convenience. The clinical outcomes data does not favor gels over injectables for symptomatic relief in hypogonadal men. A Cochrane review on testosterone therapy for male hypogonadism found no significant difference in symptom improvement between delivery routes when equivalent serum levels were achieved.

Manufacturer Copay Cards and PAP Programs

For branded products that survive step-therapy, copay assistance programs exist but carry restrictions:

• AndroGel (AbbVie): Copay card reduces out-of-pocket to $0 for commercially insured patients; not valid for government-funded plans.
• Natesto (Acerus): Patient assistance available through the manufacturer for income-qualifying uninsured patients.
• Aveed (Endo Pharmaceuticals): The REMS requirement means the drug is administered in-office; billing goes through medical benefit (J-code J3145), not pharmacy benefit. This distinction alone changes which department handles prior authorization.

J-Code vs. Pharmacy Benefit Split

Aveed and compounded testosterone (when administered in-office) bill under the medical benefit using J-codes, not through the pharmacy benefit. J3145 covers testosterone undecanoate 1 mg IM. Standard cypionate or enanthate administered in-office may bill under J3490 (unclassified drug injection) or the applicable HCPCS code depending on payer. Submitting under the wrong benefit category is a routine source of denials that is entirely avoidable with correct coding.

CMS HCPCS code lookup for testosterone injectable products is available at the CMS website.

Monitoring Requirements That Affect Ongoing Authorization Renewals

Payers require documented monitoring at PA renewal. Failing to have lab results in the chart before submitting a renewal triggers an automatic pend and often a denial. The monitoring schedule most plans recognize aligns closely with Endocrine Society guidance:

• 3 months after initiation: total testosterone (mid-cycle for injectables, 2 to 8 hours post-application for gels), hematocrit, PSA
• 12 months: repeat full panel plus bone mineral density if baseline was low
• Annually thereafter: testosterone level, hematocrit, PSA, fasting lipids

The Endocrine Society 2018 guideline states: "We recommend monitoring testosterone levels 3 to 6 months after starting treatment."

Hematocrit Thresholds and Dose Adjustment

A hematocrit above 54% is both a safety concern and a prior-auth problem. Most plans will not renew a testosterone PA if the most recent hematocrit exceeds 54% without documented dose reduction or therapeutic phlebotomy. The TRAVERSE trial (N=5,246), the largest cardiovascular safety trial of testosterone therapy to date, found the rate of polycythemia (hematocrit >54%) was 6.9% in the testosterone group vs. 0.8% in placebo at a median follow-up of 22 months. TRAVERSE results were published in the New England Journal of Medicine in 2023.

Document dose adjustments explicitly: "Hematocrit rose to 52% at 3-month follow-up; testosterone cypionate dose reduced from 100 mg weekly to 80 mg weekly on [date]. Recheck scheduled in 6 weeks."

PSA Monitoring and Urology Referral Documentation

A PSA increase of >1.4 ng/mL above baseline within any 12-month period, or an absolute PSA >4 ng/mL, requires urology evaluation before testosterone can be continued. The Endocrine Society guideline recommends referral to urology if PSA rises more than 1.4 ng/mL within any 12 months of testosterone treatment. Document the referral, the urology note, and the outcome in the chart before submitting a PA renewal. Payers increasingly require this documentation as a hard requirement, not a soft recommendation.

Appeals Strategy When the PA Is Denied

First-Level Appeal: Internal Review

File within the plan-specified window (usually 30 to 60 days from denial). Include:

• Complete lab package with collection timestamps
• Validated symptom score
• Prescriber attestation that step-therapy criteria were met or that an exception criterion applies
• Relevant published guideline excerpts (Endocrine Society 2018, AUA 2022) supporting the chosen formulation

Second-Level Appeal: External Independent Review

If the internal appeal fails, all commercial plans operating under ACA rules must offer external independent review. Independent review organizations overturn testosterone PA denials at a rate that varies by state but generally favors the patient when the diagnosis is E29.1 with two confirmatory labs. Reference the AUA and Endocrine Society guidelines explicitly in the external review submission.

State Mandate Considerations

Several states (including California, New York, and Texas) have enacted step-therapy reform laws requiring plans to grant exceptions within defined timeframes when a clinician certifies that step-therapy is clinically contraindicated. The National Conference of State Legislatures tracks these laws, and the AUA has published advocacy guidance on step-therapy reform. Know your state's statute before accepting a denial as final.

Compounded Testosterone: Billing and Compliance Considerations

503A compounding pharmacies produce testosterone cypionate, propionate, and pellet formulations outside the standard commercial supply chain. These products are not FDA-approved, cannot be billed to most commercial insurance plans as a pharmacy benefit, and do not carry NDC numbers that process through standard pharmacy adjudication.

Patients using compounded testosterone should pay cash or submit a superbill for possible reimbursement under an FSA or HSA. From a compliance standpoint, prescribing compounded testosterone when a commercially available FDA-approved product could be used raises regulatory scrutiny under 503A rules. The FDA's guidance on 503A compounding pharmacies outlines these restrictions.